From GlobeNewswire:

Adverum Biotechnologies, Inc. is set to present preliminary data from the ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet age-related macular degeneration at the 47th Annual Meeting of the Macula Society on Thursday, February 8, 2024. The presentation will include safety and efficacy data at both the 2E11 and 6E10 dose levels. LUNA was fully enrolled in August 2023. The webcast of the presentation will be available in the News and Publications section of Adverum’s website soon after the meeting.

The preliminary effectiveness and safety data from the LUNA Phase 2 study of Ixo-vec will be discussed at a conference call and webcast on the 8th of February, 2024 at 8:00 am ET. A replay of the webcast will be available on the website following the presentation.

Adverum Biotechnologies is a clinical-stage enterprise, with gene therapy as the new standard of care for prevalent ocular diseases. Considering its intravitreal (IVT) platform, the company is developing durable, single-administration therapies that eliminate the need for regular ocular injections. Adverum’s gene therapy candidate is being evaluated as a one-time, IVT injection for those with wet age-related macular degeneration. For more information, please visit www.adverum.com.

The release of initial preliminary efficacy and safety data from the LUNA Phase 2 study is subject to risks and uncertainties. Adverum is uncertain about predicting the timing of the commencement and completion of clinical trials; the results of early clinical trials not always being predictive of future clinical trials and results.

For further details, individuals may contact Adverum Investor Relations via [email protected].



Read more: Adverum Biotechnologies will Host Webcast to Review LUNA